EpiBone

EpiBone is a biotechnology company headquartered in New York City, New York that was founded in 2013 by Nina Tandon, Sarindr Bhumiratana, Gordana Vunjak-Novakovic, and Sidney Eisig. CEO and Co-Founder Nina Tandon worked on heart regeneration for her PhD, worked at McKinsey management consultancy and has an MBA.

EpiBone uses a biomedical engineering process that includes 3D printing to create individualized bone grafts using a patients own mesenchymal stem cells grown in the company's custom built bioreactor. The process involves a CT scan to determine the exact size and shape of a needed bone. A precise, personalized scaffold is created. The patient’s stem cells are cultured so that they start becoming bone cells and are placed on the scaffold and remodel into a personalized bone graft that can be implanted.

Phase 1 and 2 clinical trial Investigational New Drug (IND) clearance was granted by the FDA in 2019 for their product EpiBone-Craniomaxillofacial (EB-CMF) as a treatment for ramus continuity defects in the mandible. The product is anatomically correct and manufactured from a patient’s own adipose derived stem cells.

On June 12, 2014 EpiBone received an undisclosed amount of funding in the form of a grant from the Partnership Fund for New York City and Breakout Labs.

On October 1, 2016 EpiBone received a convertible note worth $560 thousand from Plum Alley.